Key result
Tezosentan infusion caused a dose-dependent increase in cardiac index ranging from 24.4% to 49.9% versus 3.0% with placebo in patients with class III to IV heart failure.
Why the study?
Does tezosentan improve hemodynamic parameters in patients with NYHA class III to IV heart failure?
RCT (n=61)
placebo-controlled
randomized
Does tezosentan improve hemodynamic parameters in patients with NYHA class III to IV heart failure?
Intravenous tezosentan safely improves cardiac index and reduces vascular resistance in patients with NYHA class III-IV heart failure.
No takes yet. Share an insight, caveat, or question.
Tezosentan acutely improves cardiac index in severe HF; extends endothelin antagonism as a viable acute target.
Torre‐Amione et al. (2001) conducted an RCT in Congestive Heart Failure (n=61). Tezosentan vs. Placebo was evaluated on Cardiac index. Tezosentan infusion caused a dose-dependent increase in cardiac index ranging from 24.4% to 49.9% versus 3.0% with placebo in patients with class III to IV heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: